Viewing Study NCT07245394


Ignite Creation Date: 2025-12-25 @ 1:33 AM
Ignite Modification Date: 2025-12-25 @ 11:47 PM
Study NCT ID: NCT07245394
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-11-24
First Post: 2025-09-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
Sponsor: TIDHI Innovation Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module